Premium
Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program
Author(s) -
Reynolds C. Patrick,
Kang Min H.,
Maris John M.,
Kolb E. Anders,
Gorlick Richard,
Wu Jianrong,
Kurmasheva Raushan T.,
Houghton Peter J.,
Smith Malcolm A.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25611
Subject(s) - docetaxel , cabazitaxel , taxane , in vivo , medicine , pharmacology , paclitaxel , oncology , pediatric cancer , in vitro , ovarian cancer , sarcoma , cancer , cancer research , prostate cancer , pathology , biology , androgen deprivation therapy , biochemistry , microbiology and biotechnology , breast cancer
Background Although microtubule‐destabilizing agents (principally vincristine) are in common use in pediatric oncology, the microtubule‐stabilizing taxanes are uncommonly used to treat childhood cancers. Cabazitaxel has been reported to have activity superior to that of docetaxel in preclinical models of multidrug‐resistant adult cancers, and it was active in patients who had progressed on or after docetaxel. The PPTP conducted a comparison of these two agents against the PPTP in vitro panel and against a limited panel of solid tumor xenografts. Procedures Cabazitaxel and docetaxel were tested against the PPTP in vitro cell line panel at concentrations from 0.01 to 0.1 μM and in vivo against a subset of the PPTP solid tumor xenograft models at a dose of 10 or 7.5 mg/kg on an every 4 days × 3 I.V. schedule. Results In vitro , both cabazitaxel and docetaxel had similar potency (median rIC 50 0.47 nM and 0.88 nM, respectively) and a similar activity profile, with Ewing sarcoma cells being significantly more sensitive to both agents. In vitro sensitivity to docetaxel inversely correlated with mRNA expression for ABCB1, but the correlation with ABCB1 expression was weaker for cabazitaxel. In vivo cabazitaxel demonstrated significantly greater activity than docetaxel in five of 12 tumor models, inducing regressions in six models compared with three models for docetaxel. Conclusions Cabazitaxel demonstrated superior activity compared to docetaxel. The lower cabazitaxel systemic exposure tolerated in humans compared to mice needs to be considered when extrapolating these results to the clinical setting. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.